Takeda is continuing a major overhaul of its R&D organization, transferring 300 staffers to PRA, a global clinical research organization which will now take the lead on the pharma company’s development efforts.
In a deal that PRA Chief Executive Officer Colin Shannon called “the first of its kind in the CRO industry,” Takeda says that 300 employees in the U.S. and Europe will get a chance to take new jobs at the CRO. And PRA will now be responsible for a full pipeline of research programs, running from Phase I through Phase IV post-marketing studies.
The transfer includes regulatory, pharmacovigilance and other services covering development and marketed product portfolios.
For Takeda, the latest development follows a $725 million reorganization effort announced in late July. At the time, the company said it was reducing its R&D footprint to two key centers at Shonan, Japan and Boston, U.S. A third group will operate in San Diego as the company downsizes its efforts in the U.K.
This continues a reboot triggered by the new CEO at Takeda, Christophe Weber, who’s been sending shockwaves through the company, founded in 1781.
“This partnership is a fundamental part of Takeda’s R&D transformation and represents a truly innovative approach to clinical development, unprecedented in our industry,” said Andy Plump, M.D., Ph.D., Director, Chief Medical and Scientific Officer at Takeda. “PRA has a reputation for providing tailored sourcing solutions. We believe PRA will be an ideal partner as we focus, deliver and advance our current and future pipeline.”
The best place to read Endpoints News? In your inbox.
Full-text daily reports for those who discover, develop, and market drugs. Join 17,000+ biopharma pros who read Endpoints News by email every day.Free Subscription